Full Text View
Tabular View
No Study Results Posted
Related Studies
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
This study has been completed.
Study NCT00452218   Information provided by University of Chicago

First Received on March 26, 2007.   Last Updated on September 21, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pulmonary Arterial Hypertension
Additional conditions recognized in this trial
Hypertension
Hypertension, Pulmonary
More general conditions related to this trial
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Interventions listed in this trial
Sorafenib
More general drug interventions related to this trial
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
University of Chicago
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services